In a packed San Francisco conference room last Tuesday, upbeat company representatives and scientists presented detailed clinical trial data on the first Alzheimer’s treatment shown to clearly, albeit modestly, slow the disease’s normal cognitive decline. The antibody therapy has buoyed a field marked by decades of failures. Now, it appears to be on the cusp …
The pharmaceutical companies Biogen and Eisai last week announced that a monoclonal antibody treatment reduced cognitive decline by 27% in people with early stage Alzheimer’s compared with those on a placebo after 18 months. www.science.org/content/article/news-glance-ai-regulation-renewable-energy-and-alzheimer-s-therapy? Lecanemab belongs to a class of therapies that break down or inhibit build up of amyloid plaques in the brain, …
A new monoclonal antibody treatment for Alzheimer’s disease Read More »
Earlier this week, the pharmaceutical companies Biogen and Eisai announced encouraging results from a clinical trial for patients with Alzheimer’s disease: a monoclonal antibody treatment, called lecanemab, reduced cognitive decline by 27% in people with early-stage Alzheimer’s compared with those on a placebo after a year and a half. Outside observers say the trial could …
Monoclonal antibody marks first approved Alzheimer’s treatment in nearly twenty years Read More »
Health experts across the globe are signalling alarm as they begin reporting that Omicron BA.5, the coronavirus strain that is currently outpacing other variants in infection and has become the dominant strain in the United States (US) and abroad, has the ability to reinfect people within weeks of contracting the virus. Andrew Robertson, the chief …
Subscribe our newsletter to stay updated
Copyright © 2023 | Health Issues Africa | All rights reserved.
